Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin

Shots:

• The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC
• Lannett will fund the clinical development requirements and will manage the clinical & regulatory steps specific for the FDA’s approval while HEC continues to develop the product and related manufacturing infrastructure. Both companies will share the profits of the venture
• Insulin aspart is a short-acting (fast-acting) insulin typically taken just before eating, is used to treat adults with T1D & T2D

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Lannett Company